二 | (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed. China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval. A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country. Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category. This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading. At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly. To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong. The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions. In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total. (By Tang Yuxian) 。今日，数码博主“数码闲聊站”发文称，9月或许是机圈史上最激烈的新品月，高端折叠、旗舰芯片以及旗舰手机三条产品线都将迎来大规模更新。 首先是高端折叠屏市场。按照爆料，9月将迎来华为新一代三折叠、小米首款阔折叠以及苹果首款阔折叠产品，三大厂商将在高端折叠屏市场展开正面竞争。

三 |

其中，华为已经官宣Mate XT 2将于9月7日发布，新一代三折叠手机届时正式登场。小米方面，小米CEO雷军此前宣布9月将成为小米“科技大月”，月初澎程系列正式上市，同时带来小米18 Fold，月底则将发布小米18 Pro系列。芯片领域同样堪称“神仙打架”。 9月手机市场预计将迎来小米玄戒O3、苹果A20系列、联发科天玑9600系列、高通骁龙8E6系列以及华为麒麟2026τ芯片，多家厂商的新一代旗舰芯片将集中亮相。其中，小米玄戒O3已率先发布，定位AI旗舰SoC，安兔兔跑分首次突破500万，其首发终端为小米18 Fold。而在传统直板旗舰产品线上，9月同样会迎来一轮“机海战术”。根据目前消息，iPhone 18系列、vivo X500系列、OPPO Find X10系列、华为Mate 90系列、小米18系列、荣耀Magic9系列以及iQOO 16等新一代旗舰都有望在9月集中登场。 vivo方面已确认，X500系列将在9月正式发布，并将推出X500、X500 Pro、X500 Pro Max三款机型。从目前各家厂商的产品节奏来看，今年9月不仅旗舰手机数量众多，还叠加了折叠屏形态之争和新一代旗舰芯片集中换代。苹果、华为、小米、OPPO、vivo、荣耀、iQOO等主流厂商都将参与其中，手机行业也将提前进入新一轮旗舰大战。

【本文结束】如需转载请务必注明出处：责任编辑：拾柒文章内容举报

。